Aquestive Therapeutics - AQST STOCK NEWS

Aquestive Therapeutics (Nasdaq: AQST) announced key leadership changes, appointing Timothy E. Morris to the Board of Directors and Kenneth Truitt, M.D., as Chief Medical Officer. Morris brings over 35 years of experience in executive leadership and will join the Audit Committee. Truitt, effective September 6, 2022, has over 25 years of clinical experience and aims to advance AQST-109, targeting the emergency treatment of allergic reactions. Both appointments aim to strengthen the company's pipeline and regulatory engagement, particularly with the FDA.

Aquestive Therapeutics reported second quarter 2022 financial results, revealing total revenues of $13.3 million, down from $15.3 million in Q2 2021, despite a 36% surge in revenue from its product Sympazan. The company's net loss widened to $16.3 million or $0.36 per share, compared to a $12.4 million loss, primarily due to increased R&D expenses for AQST-109. However, the firm has updated its full-year revenue guidance to $46-$49 million, up from $42-$47 million, and maintains a positive outlook for its product development and FDA dialogues.

Aquestive Therapeutics, Inc. (NASDAQ: AQST) announced its participation in the Wedbush PacGrow Healthcare Conference set for August 9-10, 2022. The management team will host a fireside chat on August 9 at 10:55 am ET and conduct investor meetings until August 10. A webcast of the chat will be available for 30 days on the company's website.

Aquestive focuses on developing innovative orally administered products, including its proprietary Sympazan® for seizures. The company is advancing a pipeline targeting CNS diseases and severe allergic reactions.

Aquestive Therapeutics, Inc. (NASDAQ: AQST) announced it will report its second-quarter results for the period ended June 30, 2022, on August 2, 2022, after market close. Investors can join a conference call on August 3, 2022, at 8:00 a.m. ET, after prior registration. The company focuses on innovative delivery methods for complex molecules and has five commercialized products and a late-stage pipeline targeting central nervous system diseases and severe allergic reactions. For more information, visit Aquestive's website.

Aquestive Therapeutics (AQST) announced positive topline results from Part 3 of the EPIPHAST study for AQST-109, an epinephrine oral film. Key findings showed a consistent Tmax of 12 minutes for sublingual administration after consuming a peanut butter sandwich, with comparable pharmacokinetics to previous datasets. In addition, swallowing the film whole with water resulted in unexpectedly high gastrointestinal absorption, indicating improved compliance potential. The ongoing EPIPHAST II study will compare AQST-109 to standard epinephrine injection methods.

Aquestive Therapeutics (AQST) announced promising results from the EPIPHAST study for AQST-109, an oral film for anaphylaxis treatment. The study demonstrated a median time to maximum concentration (Tmax) of 12 minutes, significantly faster than traditional EpiPen's 50 minutes. AQST-109 shows favorable pharmacokinetics and safety profiles. An upcoming head-to-head study with EpiPen is set for Q3 2022, with plans to seek an End-of-Phase 2 meeting with the FDA shortly thereafter.

Aquestive Therapeutics (NASDAQ: AQST) has completed a registered direct offering, raising approximately $8.5 million by selling 8,850,000 shares at $0.96 each to an institutional investor and $1.09 for its executives. The warrants issued are exercisable after six months at a price of $0.96. CEO Daniel Barber emphasized the focus on profitability and cash generation amidst market challenges, particularly regarding the FDA review of Libervant and the development of AQST-109. The offering is executed under Form S-3 registration with the SEC.

Aquestive Therapeutics (NASDAQ: AQST) announced participation in the JMP Securities Life Sciences Conference on June 15-16, 2022. The management team will conduct a fireside chat on June 16 at 9:00 am ET and hold investor meetings throughout the conference. A webcast of the presentation will be available on the company's Investor Relations website for 30 days post-event. Aquestive focuses on developing innovative oral medications to enhance patient care, with five products currently on the market, including Sympazan® for seizure treatment.

Aquestive Therapeutics (NASDAQ: AQST) announced a definitive agreement for a registered direct offering of 8,850,000 shares of common stock and warrants, generating approximately $8.5 million in gross proceeds. Shares will be sold at $0.96 each to a healthcare-focused institutional investor and at $1.09 to certain executives. The offering is expected to close around June 8, 2022, pending customary conditions. The funds will be allocated for general corporate purposes. A.G.P./Alliance Global Partners is the sole placement agent for this offering.